These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9441326)

  • 1. [Pharmacological considerations in the economic evaluation of glycopeptides].
    García-Quetglas E; Sádaba B; Honorato J
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():68-73. PubMed ID: 9441326
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
    Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].
    Bouza E; Rodríguez-Créixems M; Muñoz P
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():52-8. PubMed ID: 9441324
    [No Abstract]   [Full Text] [Related]  

  • 4. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vancomycin versus teicoplanin use as antibiotic prophylaxis in surgery].
    Zas-Garcia I; Gutierrez-Urbon JM; Martin-Herranz I
    Farm Hosp; 2015 Nov; 39(6):399-401. PubMed ID: 26618383
    [No Abstract]   [Full Text] [Related]  

  • 7. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis.
    Bhavnani SM; Prakhya A; Hammel JP; Ambrose PG
    Clin Infect Dis; 2009 Sep; 49(5):691-8. PubMed ID: 19635023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glycopeptides].
    Hayashi I
    Nihon Rinsho; 2001 Apr; 59(4):761-70. PubMed ID: 11305003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacterial endocarditis treated with intramuscular teicoplanin.
    Chauhan S; D'Cruz S; Sachdev A; Singh R
    Singapore Med J; 2007 Sep; 48(9):e248-9. PubMed ID: 17728952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin.
    Salaria M
    Indian Pediatr; 2001 Apr; 38(4):372-5. PubMed ID: 11313506
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci.
    Bourgeois I; Pestel-Caron M; Lemeland JF; Pons JL; Caron F
    Antimicrob Agents Chemother; 2007 Feb; 51(2):740-3. PubMed ID: 17116684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin].
    Gil M; Otth L; Wilson M; Arce E; Zaror A; Lizama V
    Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
    Atahan E; Gul M; Ergun Y; Eroglu E
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues.
    Craven PC
    Hosp Formul; 1993 Jan; 28 Suppl 1():41-5. PubMed ID: 10123838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are glycopeptides still appropriate and convenient for empiric use?
    Gonzalez-Ruiz A; Richardson J
    J Chemother; 2008 Oct; 20(5):531-41. PubMed ID: 19028614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of teicoplanin on Staphylococcus aureus with heterointermediate susceptibility to glycopeptides in experimental infective endocarditis model.
    Vas KE; Török Á; Cordoş B; Vancea S; Brassai A; Székely E
    J Chemother; 2016 Oct; 28(5):446-9. PubMed ID: 25976829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.